P37 is a new isoform of PI3K p110 that increases cell proliferation and is overexpressed in tumors

Oncogene

Volumn 31, Issue 27, 2012, Pages 3277-3286

  Fransson, S ^a   Uv, A ^a   Eriksson, H ^a   Andersson, M K ^a   Wettergren, Y ^b   Bergo, M ^a   Ejeskar K ^a,c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITY OF SKÖVDE   (Sweden)

Author keywords

colorectal cancer; ovarian cancer; p110 ; p37d; p85; RAS

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P110; PROTEIN P110 DELTA; PROTEIN P37; PROTEIN P37 DELTA; PROTEIN P85; RAS PROTEIN; UNCLASSIFIED DRUG; ISOENZYME; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CD PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CATALYSIS; CELL PROLIFERATION; COLORECTAL TUMOR; CONTROLLED STUDY; DNA CONTENT; DOWN REGULATION; DROSOPHILA MELANOGASTER; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR INTERACTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; RNA SPLICING; ALTERNATIVE RNA SPLICING; ANIMAL; BODY SIZE; CANCER INVASION; CELL STRAIN HEK293; FEMALE; GENE EXPRESSION REGULATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; MALE; METABOLISM; NEOPLASM; PATHOLOGY; PHOSPHORYLATION;

ALTERNATIVE SPLICING; ANIMALS; BODY SIZE; CELL PROLIFERATION; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; DOWN-REGULATION; DROSOPHILA MELANOGASTER; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; ISOENZYMES; MALE; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASM INVASIVENESS; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS;

EID: 84863722890     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.492     Document Type: Article

References (29)

1. Bilancio A, Okkenhaug K, Camps M, Emery JL, Ruckle T, Rommel C et al. (2006). Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells. Blood 107: 642-650. (Pubitemid 43076389)
2. Bischof J, Maeda RK, Hediger M, Karch F, Basler K. (2007). An optimized transgenesis system for drosophila using germ-linespecific phiC31 integrases. Proc Natl Acad Sci USA 104: 3312-3317. (Pubitemid 46364156)
3. Caren H, Fransson S, Ejeskar K, Kogner P, Martinsson T. (2007). Genetic and epigenetic changes in the common 1p36 deletion in neuroblastoma tumours. Br J Cancer 97: 1416-1424. (Pubitemid 350114785)
4. Chagpar RB, Links PH, Pastor MC, Furber LA, Hawrysh AD, Chamberlain MD et al. (2010). Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase. Proc Natl Acad Sci USA 107: 5471-5476.
5. Chen LC, Hao CY, Chiu YS, Wong P, Melnick JS, Brotman M et al. (2004). Alteration of gene expression in normal-appearing colon mucosa of APC(min) mice and human cancer patients. Cancer Res 64: 3694-3700. (Pubitemid 38657950)
6. Ciraolo E, Iezzi M, Marone R, Marengo S, Curcio C, Costa C et al. (2008). Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development. Sci Signal 1: ra3.
7. Denley A, Kang S, Karst U, Vogt PK. (2008). Oncogenic signaling of class I PI3K isoforms. Oncogene 27: 2561-2574. (Pubitemid 351550883)
8. Engelman JA, Luo J, Cantley LC. (2006). The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7: 606-619. (Pubitemid 44100518)
9. Foukas LC, Berenjeno IM, Gray A, Khwaja A, Vanhaesebroeck B. (2010). Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc Natl Acad Sci USA 107: 11381-11386.
10. Fransson S, Martinsson T, Ejeskar K. (2007). Neuroblastoma tumors with favorable and unfavorable outcomes: significant differences in mRNA expression of genes mapped at 1p36.2. Genes Chromosomes Cancer 46: 45-52. (Pubitemid 44772871)
11. Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH et al. (2008). Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 454: 776-779.
12. Kang S, Denley A, Vanhaesebroeck B, Vogt PK. (2006). Oncogenic transformation induced by the p110beta,-gamma, and-delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci USA 103: 1289-1294. (Pubitemid 43191158)
13. Kok K, Nock GE, Verrall EA, Mitchell MP, Hommes DW, Peppelenbosch MP et al. (2009). Regulation of p110delta PI 3-kinase gene expression. PLoS ONE 4: e5145.
14. Luo J, Field SJ, Lee JY, Engelman JA, Cantley LC. (2005). The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex. J Cell Biol 170: 455-464. (Pubitemid 41126944)
15. Odin E, Wettergren Y, Nilsson S, Willen R, Carlsson G, Spears CP et al. (2003). Altered gene expression of folate enzymes in adjacent mucosa is associated with outcome of colorectal cancer patients. Clin Cancer Res 9: 6012-6019. (Pubitemid 38018088)
16. Patton DT, Garcon F, Okkenhaug K. (2007). The PI3K p110delta controls T-cell development, differentiation and regulation. Biochem Soc Trans 35: 167-171. (Pubitemid 46596459)
17. Philp AJ, Campbell IG, Leet C, Vincan E, Rockman SP, Whitehead RH et al. (2001). The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res 61: 7426-7429. (Pubitemid 32995029)
18. Polley AC, Mulholland F, Pin C, Williams EA, Bradburn DM, Mills SJ et al. (2006). Proteomic analysis reveals field-wide changes in protein expression in the morphologically normal mucosa of patients with colorectal neoplasia. Cancer Res 66: 6553-6562. (Pubitemid 44085610)
19. Rameh LE, Chen CS, Cantley LC. (1995). Phosphatidylinositol (3,4,5)P3 interacts with SH2 domains and modulates PI 3-kinase association with tyrosine-phosphorylated proteins. Cell 83: 821-830.
20. Sawyer C, Sturge J, Bennett DC, Hare MJ, Allen WE, Bain J et al. (2003). Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta. Cancer Res 63: 1667-1675. (Pubitemid 36373660)
21. Skolnik EY, Margolis B, Mohammadi M, Lowenstein E, Fischer R, Drepps A et al. (1991). Cloning of PI3 kinase-associated p85 utilizing a novel method for expression/cloning of target proteins for receptor tyrosine kinases. Cell 65: 83-90. (Pubitemid 121001216)
22. Sujobert P, Bardet V, Cornillet-Lefebvre P, Hayflick JS, Prie N, Verdier F et al. (2005). Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 106: 1063-1066. (Pubitemid 41076455)
23. Taniguchi CM, Winnay J, Kondo T, Bronson RT, Guimaraes AR, Aleman JO et al. (2010). The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling. Cancer Res 70: 5305-5315.
24. Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC. (2005). Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci 30: 194-204. (Pubitemid 40463309)
25. Vanhaesebroeck B, Welham MJ, Kotani K, Stein R, Warne PH, Zvelebil MJ et al. (1997). P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci USA 94: 4330-4335. (Pubitemid 27194241)
26. Vogt PK, Gymnopoulos M, Hart JR. (2009). PI 3-kinase and cancer: changing accents. Curr Opin Genet Dev 19: 12-17.
27. Wettergren Y, Odin E, Nilsson S, Carlsson G, Gustavsson B. (2008). p16INK4a gene promoter hypermethylation in mucosa as a prognostic factor for patients with colorectal cancer. Mol med 14: 412-421.
28. Yu J, Zhang Y, McIlroy J, Rordorf-Nikolic T, Orr GA, Backer JM. (1998). Regulation of the p85/p110 phosphatidylinositol 30-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol Cell Biol 18: 1379-1387. (Pubitemid 28100902)
29. Zhao L, Vogt PK. (2008). Class I PI3K in oncogenic cellular transformation. Oncogene 27: 5486-5496.